Related Experiment Video

Updated: Jun 4, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes

Yi Lin1, Zhongjie Sun

  • 1Department of Physiology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.

The Journal of Endocrinology
|February 11, 2011
PubMed

Insights

Tri-iodothyronine (T₃) treatment improved kidney function and reduced structural damage in a mouse model of type 2 diabetes. T₃ enhanced insulin signaling, offering a potential new therapy for diabetic nephropathy.

Area of Science:

  • Endocrinology
  • Nephrology
  • Metabolic Diseases

Background:

  • Diabetic nephropathy is a common complication of diabetes, often progressing despite glycemic control.
  • Lower serum-free tri-iodothyronine (T₃) levels are observed in type II diabetes patients.
  • Current therapies do not fully halt diabetic nephropathy progression.

Purpose of the Study:

  • To investigate the therapeutic potential of T₃ in improving diabetic nephropathy.
  • To test the hypothesis that T₃ treatment ameliorates kidney damage in a type II diabetes mouse model.

Main Methods:

  • Male db/db mice, a model for type II diabetes, were treated with T₃ for 4 weeks.
  • Assessed urinary albumin excretion, blood glucose, and kidney histology.
  • Measured kidney transforming growth factor-β1 (TGF-β1) expression and phosphatidylinositol 3-kinase (PI3K) activity.
  • Investigated the role of PI3K by using a PI3K inhibitor (LY294002).

Main Results:

  • T₃ treatment significantly reduced albuminuria, indicating improved kidney function.
  • T₃ attenuated interstitial fibrosis, glomerulosclerosis, and prevented glomerular loss in diabetic mice.
  • T₃ restored renal PI3K activity, decreased hyperglycemia, and reduced renal TGF-β1 expression.
  • The beneficial effects of T₃ were blocked by a PI3K inhibitor.

Conclusions:

  • T₃ treatment ameliorates renal structural damage and improves kidney function in a type II diabetes mouse model.
  • T₃ exerts its protective effects by enhancing insulin signaling, specifically PI3K activity.
  • T₃ represents a potential therapeutic strategy for managing diabetic nephropathy.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...